About Siliphos
Siliphos (silybin phytosome, IdB 1016) is a patented complex of silybin — the most potent flavolignan in milk thistle (~50–70% of silymarin) — bound to phosphatidylcholine. Standard silymarin has ~2% oral bioavailability; the phytosome achieves ~10× higher plasma silybin levels in human pharmacokinetic studies (peak 1,004 vs 139 ng/mL). Phosphatidylcholine is itself hepatoprotective, making the combination synergistic for liver health. A Phase III double-blind trial (n=179, 12 months) showed significant improvements in liver enzymes, insulin resistance (HOMA-IR), and liver histology in NAFLD patients. A pediatric trial (n=50) showed significant AST reductions in chemotherapy-induced hepatotoxicity. Silybin does not show significant drug interactions at standard doses. Safety margin is wide — no significant side effects below 10 g/day. Minor GI discomfort is rare (<6% of patients). No established RDA/UL.
What Siliphos supports
- Supports liver health with ~10× absorption over standard milk thistle
- Clinically shown to improve liver enzymes and histology in NAFLD
- Phase III trial demonstrated improvements in insulin resistance
- Phosphatidylcholine carrier is itself hepatoprotective and synergistic
How much Siliphos to take
Clinical studies typically use 360–1080 mg of Siliphos. Clinical studies use 120–360 mg/day of silybin content from phytosome form. Siliphos is ~30% silybin by weight, so 360–1,080 mg of the complex delivers the clinical range. Most supplements provide 180 mg Siliphos per capsule at 2–3 capsules/day. The landmark Phase III NAFLD trial used Realsil (silybin 188 mg/day as phytosome).
- Effective range
- 360–1080 mg
Clinical evidence
Moderate clinical evidence. Phase III trial (179 patients, 12 months) showed significant liver improvements in NAFLD
Examine.com